Shares of Femasys cratered 15.3% to $2.50 after the company announced a $30 million private placement that could flood the market with new stock. For a company that only recently saved its Nasdaq listing through a 1-for-20 reverse stock split in June, the deal raises a pointed question: is this survival financing or a genuine growth catalyst?
The Share Count Could Nearly Triple, Crushing Existing Holders. The deal involves 9.37 million shares of common stock and pre-funded warrants, plus warrants to purchase 18.75 million additional shares. After the June reverse split, Femasys had roughly 3 million post-split shares outstanding. Even the initial tranche alone would multiply the share count several times over. If every warrant is exercised, the company touts potential proceeds "of up to $90 million" — but at the cost of massive ownership dilution for anyone who held stock before the deal.
The Pricing Tells You Who Has Leverage — And It's Not Shareholders. Securities were priced at $3.20 per share with warrants exercisable at $2.95 — both already underwater with shares at $2.50. The financing was led by new institutional investor Nantahala Capital, with participation from Rosalind Advisors and Femasys management. That management bought in is a positive signal, but the steep discount and warrant overhang show investors demanded aggressive terms.
A History of Near-Delisting Shadows This Deal. Femasys executed a 1-for-20 reverse stock split effective June 5, 2026 , and only regained Nasdaq compliance on June 24 — barely six weeks before this placement. In 2025, revenue was just $2.29 million while losses totaled $18.63 million. The company is burning cash far faster than it earns, making outside capital a necessity, not a choice.
The Clinical Story Is Real, but Revenue Must Catch Up. Published trial data showed Femasys's lead fertility treatment achieved "more than double the pregnancy rate" of the standard approach.
Its non-surgical birth control product holds regulatory approvals in Europe, the UK, and New Zealand.
The stock's 52-week range of $2.29 to $22.20 reflects wild swings between hope and dilution fear. With $30 million now secured, Femasys buys time — but shareholders just paid a steep price in ownership to get it.